Division of Gastroenterology & Liver Diseases

Clinical Studies

Clinical Studies

  1. ILLUMINATE
    A randomized study of stopping treatment at 24 weeks or continuing treatment to 48 weeks in treatment-naive subjects with genotype 1 chronic hepatitis C who achieve an extended rapid viral response (ERVR) while receiving Telaprevir, Peginterferon Alfa2a (Pegasys), and Ribavirin (Copegu)
    Study Sponsor: Vertex Pharmaceuticals, Inc.
    Principal Investigator: John F. Reinus, MD
  2. SELECT-2
    A phase 2B, partially blinded, randomized study in treatment-naive subjects with HCV genotype 1 to compare the efficacy, safety, and tolerability of three doses of LoctEron plus Ribavirin given biweekly in comparison with  PEG-Intron plus Ribavirin given weekly.
    Study Sponsor: Biolex Therapeutics
    Principal Investigator: John F. Reinus, MD
  3. ELEVATE
    A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of Eltrombopag to reduce the need for platelet transfusion in thrombocytopenic subjects with chronic liver disease undergoing elective invasive procedures.
    Study Sponsor: GlaxoSmithKline
    Principal Investigator: Hatef Massoumi, MD 

Investigator-Initiated Hepatology Studies

  1. Proteomics as a Tool for Discovery of Serum Markers of Chronic Liver Disease and Hepatocellular Carcinoma
    Investigators seek to discover candidate plasma biomarkers that are predictive of early HCC.
    Principal Investigator: Allan W. Wolkoff, MD
  2. Establishment of a Montefiore-Einstein Liver Center Hepatic Tissue and Serum Repository
    Investigators seek to develop a bank of serum and liver tissue. The tissue is to be derived from explanted (removed) hepatic tissue and serum obtained during the course of standard clinical care.
    Principal Investigators: Allan W. Wolkoff, MD and Paul J. Gaglio, MD
  3. Liver Transplant Social Support Survey
    The survey’s purpose is to determine the extent to which poor social support impedes listing for liver transplant and the extent to which programs employ internal or external resources to augment social support for vulnerable patients.
    Principal Investigator: John F. Reinus, MD

 

 

 

 

 

 

Contact Us

Albert Einstein College of Medicine
625 Ullmann Building
1300 Morris Park Avenue
Bronx, NY 10461

Phone: 718.430.2098

 More info 

 

 

 

 

 

Click here to log in